Clin2
NCT07412405Possibly a fitNot yet recruiting

CAR-T cell therapy for advanced blood cancers

Adult B-cell Acute Lymphoblastic LeukemiaFollicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia

Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.

This trial tests a personalized cancer treatment called CAR-T therapy. It uses your own immune cells, which are modified in a lab to fight your specific type of blood cancer, and then given back to you. The goal is to see if this treatment is safe and feasible when produced locally.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
12 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You must be 18 or older.
  • You must have a CD19-positive blood cancer (like certain lymphomas or leukemias) that has returned or not responded to past treatments.
  • Your cancer must be measurable, meaning doctors can track it with tests.
  • You need to be generally healthy enough for treatment, with adequate organ function (like heart, lungs, liver, and kidneys).
  • You must agree to use highly effective birth control during the study and for a year after treatment, if you could become pregnant or get someone pregnant.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03676504Recruiting· Phase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers

This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.

Heidelberg
NCT01853631Recruiting· Phase 1
CAR T-cell therapy for CD19-positive B-cell blood cancers

This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).

Houston, Texas
NCT05281809Recruiting· Phase 2
CAR T-cell therapy made locally for B-cell blood cancers

This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.

Pittsburgh, Pennsylvania
NCT05705570Recruiting· Phase 1
CAR-T for CD19-positive relapsed or resistant blood cancers

This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.

São Paulo, São Paulo
NCT07316907Not yet recruiting· Phase 1
CAR-T cell therapy for blood cancers that have returned or not responded

This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.

Zhenjiang, Jiangsu
NCT06227026Recruiting· Phase 1
CAR-T cell therapy for blood cancers that returned

This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.

Salt Lake City, Utah

Hear when a new Chronic Lymphocytic Leukemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.